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1. Introduction
In most countries, cancer ranks as one of the leading
causes of death before the age of 70 years. Accord-
ing to recently published estimates, 19.3 million new
cancer cases and around 10 million cancer deaths oc-
curred worldwide in 2020. Among the different types,
female breast cancer was the most frequently diag-
nosed cancer (11.7% of all cancer cases), surpassing
lung cancer [1, 2]. Approximately 15–20% of breast
cancer cases can be characterized by an overexpres-
sion of human epidermal growth factor receptor 2
(HER2) [3, 4], and these cases tend to be more ag-
gressive than the other types of breast cancers, re-
spond more poorly to chemotherapy [5] and have a
higher recurrence rate [6] and metastasis potential
[4, 7, 8]. The use of anti-HER2 agents has yielded
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good levels of efficacy and substantially improved
outcomes of patients with HER2-positive breast can-
cers; however, increasing drug resistance remains a
challenge [4, 7, 8].
Lapatinib (LAP) is a potent and reversible dual in-
hibitor of both HER1 (also known as epidermal
growth factor receptor, or shorty EGFR) and HER2
tyrosine kinases [9]. The marketed film-coated tablet
formulation contains the ditosylate monohydrate salt
(LAP-DT), and it is currently approved for the treat-
ment of certain cases of advanced or metastatic
breast cancer in combination with capecitabine or
letrozole [10]. Although LAP displays a high selec-
tivity towards the abovementioned tyrosine kinases,
it is also plagued by being far from optimal pharma-
cokinetic properties. LAP is reported to be a Bio-
pharmaceutics Classification System (BCS) Class IV
drug [11], characterized by low bioavailability [12],
associated with poor, pH-dependent aqueous solu-
bility and low permeability [13]. It also displays high
interpatient variability, and both food intake and gas-
tric pH affect its bioavailability [12, 14, 15]. Due to
these drawbacks, large daily doses (1250–1500 mg)
are needed, taken once daily, in the form of 5–
6 tablets, which can decrease patient compliance and
increase the side effects of the anticancer drug. Im-
proving the oral bioavailability of the tyrosine kinase
inhibitor through a novel formulation with enhanced
solubility and dissolution rate could potentially re-
duce daily doses, improve treatment outcomes, and
possibly reduce the side effects.
There are several well-known solubility enhancement
techniques, such as salt- or prodrug formation, parti-
cle size reduction, complexation, emulsion formation,
and preparation of solid dispersions, just to name a
few [16–19]. Some of these techniques were also ap-
plied in order to enhance the solubility of LAP.
Song et al. [20] used spray drying to prepare solid
dispersion of LAP and four frequently used polymers
in the pharmaceutical industry, namely Soluplus®,
poly vinylpyrrolidone vinyl acetate (PVPVA), hy-
droxypropyl methylcellulose acetate succinate (HPM-
CAS), and hydroxypropyl methylcellulose phtha-
late (HPMCP). The authors’ findings indicate a large
increase in the dissolution of LAP from the solid dis-
persions compared to that of neat LAP (~5%). The
dissolution experiments were conducted in 500 ml of
0.2% (w/v) sodium dodecyl sulfate (SDS) medium
in water at 37°C. SDS was used to increase the ap-
parent solubility of LAP. The best dissolution results
(~80% LAP dissolved after 120 min) was obtained
with solid dispersions prepared with HPMCAS at
40% drug loading. Hu et al. [21] used solvent rotary
evaporation (SRE) and hot-melt extrusion (HME) to
prepare solid dispersion of LAP, Soluplus®, and
Poloxamer 188 with a particle size of ~150 μm. The
dissolution media was 900 ml of 0.1 N HCl with 2%
poly sorbate 80 at 37°C. To compensate for the gela-
tion tendency of Soluplus®, thus inhibiting the disso-
lution of LAP, 5 w/w% potassium bicarbonate was
added to all samples. Under these conditions, ~60%
of the free LAP dissolved after 60 minutes, whereas
the solid dispersion prepared by SRE released ~92%
of the drug under the same time period. The authors
concluded that SRE was a better way to produce solid
dispersions for the studied system than HME, since
in the former, all LAP was in the amorphous state,
whereas in the latter some of the LAP was still in the
crystalline state. Mitrabhanu et al. [22] prepared solid
dispersions of LAP and Eudragit® EPO (cationic), Eu-
dragit® L 100-55 (anionic), HPMCP HP-55 (anionic),
HPMC-AS (anionic), and Povidone (polyvinyl
pyrrolidone) K30 (non-ionic) polymers at different ra-
tios. Solvent-controlled coprecipitation, fusion, nano-
precipitation, and spray drying techniques were em-
ployed to prepare supersaturated solid dispersions.
The authors claim that solid dispersion significantly
improves the dissolution of LAP in the studied disso-
lution media, indifferent from the pH. Further studies
showed that amorphization of LAP by preparing core-
shell nano particles [23] or incorporating LAP and
doxorubicin into block copolymer micelles could in-
crease the dissolution and bioavailability [24].
The abovementioned research suggests that solid dis-
persion preparation and amorphization of LAP in-
creases the solubility and the dissolution of the drug.
To the authors’ knowledge, electrospinning was not
employed to prepared solid dispersion of LAP. In re-
cent years electrospinning has become a convenient
and easily accessible method to prepare solid disper-
sion of different drug-polymer systems, as is summa-
rized recently by Yu et al. [25] in review. The pro-
duced fibers are in the sub-micron or couple of mi-
crometer range, thus increasing the surface-to-volume
ratio of the produced fiber mats, which could also in-
fluence the disintegration rate of the solid dispersion,
thus the dissolution of the encapsulated active phar-
maceutical ingredient (API) [26, 27]. The working
principle of electrospinning has been discussed exten-
sively in the literature. Briefly, the electrospinning
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process involves the preparation of a polymeric so-
lution with suitable viscosity and conductivity which
is pumped through a capillary or needle with the help
of a syringe pump. A high voltage DC source is used
to create an electric field between the capillary and
a collector plate. Usually, the positive potential of the
voltage source is connected to the needle, and the
collector is grounded. The positive charges in the
polymeric solution distort the droplet at the end of
the capillary creating the so-called Taylor cone [28]
that produces a polymer solution jet traveling from
the capillary to the collector. In the process, the sol-
vent evaporates, and the solid fibers deposit onto the
collector [29–33].
The aim of this work was to prepare solid dispersion
of LAP and PVP with electrospinning technique to
increase the solubility and dissolution of LAP for fu-
ture formulations that can be efficient in breast can-
cer therapy. Furthermore, we wished to determine
the optimal electrospinning conditions that result in
a bead-free fiber mat solid dispersion, then to exam-
ine the microstructure of the produced fiber mats and
benchmark the dissolution of LAP from the solid
dispersion to the pure crystalline LAP.
2. Experimental
2.1. Materials
Lapatinib as a ditosylate monohydrate salt was ob-
tained as a gift sample from a local pharmaceutical
company in Targu Mures, Romania. Ethanol (EtOH,
Merck, ACS grade), dimethylformamide (DMF,
Sigma Aldrich, ACS grade), dimethyl sulfoxide
(DMSO, Merck, ACS grade), polyvinyl pyrrolidone
(PVP K90, Sigma Aldrich, 1–1.7 M g/mol), toluene
(GC quality, Merck, Germany) were obtained through
local vendors and used without further purification.
Hydrochloric acid (32%) was from Riedel-de-Haen,
while sodium dihydrogen phosphate and sodium hy-
droxide granules were obtained from Merck (ACS
grade). Distilled water was used for the preparation
of all aqueous solutions, apart from those for chro-
matographic purposes. For the latter, ultrapure, deion-
ized water was used, as prepared by a Barnsted Nano -
pure Diamond Barnstead International Company,
Iowa, USA water purification system.
2.2. Polymeric solution preparation
The polymer solution was prepared by the dissolu-
tion of 100 mg of LAP-DT in 1.5 ml of DMF and
1.5 ml of EtOH that resulted in a clear yellow solu-
tion. Afterwards, 480 mg PVP was added, resulting
in 15 w/w% PVP and 3.1 w/w% LAP-DT concentra-
tion. The mixture was stirred by a magnetic stirrer, JK
SMS HS (JKI, Shanghai, China), at 20°C for 15 min-
utes at 500 rpm (rotation per minute) to obtain a clear,
homogeneous, yellow, viscous polymeric solution.
2.3. Fiber production by electrospinning
Fiber mat production was carried out on a custom-
built single capillary electrospinning setup [34].
The syringe, containing the polymeric solution, was
connected by a 3.2 mm inner diameter PTFE tubing
to a needle and placed into a syringe pump (Ascor
AP 12, Ascor Med, Warsaw, Poland). The 0.8 mm
inner diameter needle was connected to the positive
potential outlet of a high voltage DC power supply
(ES50, Gamma High Voltage Research, USA)
while the collector was grounded. A custom-built
rotating drum collector (115 mm in diameter) was
employed for fiber collection at 300 rpm. The nee-
dle was positioned at the center of the drum during
the electrospinning process. The electrospinning
process was carried out at 20 °C and 30% relative
humidity, while the applied voltage (V) was set to
14 kV, the needle-to-collector distance (D) to
10 cm, and the flow rate of the polymer solution
was 0.9 ml/h.
2.4. Scanning electron microscopy (SEM)
SEM images were taken by a JEOL 6380LA (Japan)
type scanning electron microscope at 15 kV on Au
sputter-coated samples. The average fiber diameter
was determined based on the diameter of 200 ran-
domly selected fibers, measured in 5 SEM images
taken at different parts of the sample. ImageJ soft-
ware was used to measure the fiber diameters on the
SEM images.
2.5. Differential scanning calorimetry (DSC)
DSC measurements were performed on a DSC Q2000
(TA Instruments, USA) instrument in a heat/cool/heat
cycle in the temperature range of 30 to 300 °C at
10°C/min heating/cooling rate. Samples (5–10 mg)
were weighed and placed into aluminum pans. The
measurements were carried out in nitrogen atmos-
phere (purge flow: 50 ml/min), while an empty alu-
minum sample holder of the same type was used as
reference.
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2.6. Raman spectroscopy
Raman spectroscopy was carried out on a Horiba
Jobin Yvon (France) Labram type instrument with
an external laser operating at 785 nm wavelength at
80 mW power coupled with an Olympus BX-40 type
optical microscope. The spectra were collected be-
tween 1650–430 cm–1 wavenumbers.
2.7. Gas chromatographic (GC) analysis of
residual solvents
Determination of residual solvent was performed on
a Shimadzu GC-8A gas chromatograph with FID de-
tector (Shimadzu, Japan). A Porapak-N 80/100 GC
column was used with the following dimensions:
7.0 Ft (1.2 m) × 1/8 in. × 2.1 mm (L×O.D.×I.D.).
Argon (Grade 4.7, Romsif Impex SRL, Romania)
was used as the carrier gas; the pressure on the col-
umn was 2 kg/cm2. Other method parameters were
as follows:
– column oven temperature: 230°C, isothermal;
– FID detector settings: 230 °C, hydrogen (Grade
4.5, Linde Romania; 1 kg/cm2), air (1 kg/cm2);
range: 1, attenuation: 2;
– injector temperature: 220°C;
– manual injection (0.4 µl), using a Hamilton GC
precision glass syringe.
Samples and standards were prepared in toluene. Ap-
proximately 32 mg LAP-PVP nanofiber sample was
weighted and cut into a 5×5 mm2 pieces, sonicated
in 2 ml toluene for 60 mins, then centrifuged for
5 mins at 4000 rpm. A volume of 0,4 µl was injected
into the apparatus using a precision GC syringe. All
samples were prepared in triplicate.
The linearity of the method ranged between 5–
100 ppm in the case of EtOH and 100–1000 ppm for
DMF. The accuracy and precision of the method
were tested at three concentration levels. The preci-
sion of the method expressed as RSD value was
below 5.4% and relative errors for accuracy were
lower than 9% for both analytes. The retention times
of EtOH and DMF were 1.15 min and 2.1 min, re-
spectively.
2.8. Determination of drug content
LAP content of the prepared nanofibrous mat was
performed using high-performance liquid chro-
matography (HPLC). The analyses were performed
on a Finnigan Surveyor system (Thermo Finnigan,
San Jose, CA, USA), equipped with a quaternary
pump, an autosampler with a column thermostat, and
a dual-wavelength detector. Chromquest 4.0 was
used for data acquisition and analysis. The chro-
matographic column employed was a Hypersil BDS
C18 100×4.6 mm, 3 µm average particle size (Ther-
mo Fischer Scientific, Waltham, USA). The mobile
phase consisted of 50 mM phosphate buffer solution
pH 3.0 and acetonitrile 60:40 (v/v%). Separations
were performed at a column temperature of 45 °C,
using a 1.5 ml/min flow rate. Detection was per-
formed at 309 nm. Three separate samples were pre-
pared, as follows: ~58 mg nanofibrous mat was
weighted, cut into smaller pieces, and dissolved in a
10 ml amber volumetric flask using DMF. After com-
pletion to sign with DMF, 1 ml of the obtained solu-
tion was diluted to 10 ml with phosphate buffer
pH 3.0. The reference solution was prepared in the
same manner after weighing 10 mg of LAP. Dupli-
cate injections were employed in all cases.
2.9. Solubility determination
Solubility of LAP-DT was determined in HCl 0.1 N,
water, and 0.2 M phosphate buffer pH 6.8, in dupli-
cate. Briefly, 5 mg of LAP was weighed in a glass
vial and 5 mL media was added. The suspension was
sonicated for 120 minutes in an ultrasonic bath, under
constant cooling with ice, to maintain the tempera-
ture at approximately 20±2°C. After completion, the
samples were filtered through 0.45 µm PVDF filters
(Chromafil Xtra PVDF-45-25, Macherey-Nagel,
Düren, Germany), discarding the first 4 mL The
abovementioned chromatographic conditions were
used for the determination of the active, using the
external standard method.
2.10. In vitro dissolution studies
Dissolution studies were performed in an in-house
assembled small-volume dissolution setup, as de-
scribed in our earlier work [35, 36]. Dissolution vol-
ume was 20 ml, maintained at 37±1°C, using an Er-
weka ET-1500I (Erweka, Hensenstamm, Germany)
immersion thermostat. Two dissolution tests were
performed, using HCl 0.1 N and 0.2 M phosphate
buffer pH 6.8 as dissolution media. Samples of the
active substance (~10 mg LAP) and nanofibrous
mats, corresponding to the same concentration of the
active (~58.5 mg), were placed in glass tubes and
stirred with Teflon coated magnetic stir bars at
200 rpm (JKI magnetic stirrer, JKI, Shanghai, China).
At predetermined time points (1, 3, 5, 10, 15 and
30 mins), 1–1 ml of the sample was withdrawn and
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filtered through 0.45 µm PVDF filters (Chromafil
Xtra PVDF-45-25, Macherey-Nagel, Düren, Ger-
many). The dissolution media was replaced with the
same volume of preheated dissolution media. The
abovementioned chromatographic parameters were
used for the determination of the dissolved active,
using the external standard method.
3. Results and discussion
3.1. Fiber mat characterization
In this study, we selected PVP due to our experience
and previous results obtained as a polymeric carrier
in producing nanofiber-based solid dispersions via
electrospinning [37, 38]. In order to increase the LAP
content in the polymeric solutions yet still use a sol-
vent that dissolves PVP, we selected DMF and DMSO
for the first experiments. DMSO is a lower toxicity
solvent, which is desirable in pharmaceutical appli-
cations. It was determined that 150 mg of LAP-DT
dissolves in 5 ml of DMSO, resulting in a clear yel-
low solution. To produce LAP-loaded PVP fibers, a
13 w/w% PVP solution was prepared containing
2.3 w/w% LAP in DMSO. The electrospinning
process resulted in the formation of a Taylor cone
and a stable polymer jet at multiple conditions; how-
ever, no solid fibers were obtained, even at 50 kV
applied voltage, rather a wet layer formed on the col-
lector. In order to increase the volatility of the solu-
tion, EtOH was used in model experiments up to a
1:1 ratio, however, the results were the same.
Next, we examined DMF as solvent. 13 w/w% PVP
solution was prepared with 2.6 w/w% LAP in DMF;
however, we were unable to produce fibers; instead,
a thin film formed. Satisfactory results were obtained
when EtOH was introduced in 1:1 (v:v) ratio to DMF.
A systematic study of the electrospinning process
parameters of voltage (V), collector distance (D) and
flow rate (F) suggested that stable fiber formation
occurred at D = 10 cm and V = 13–14 kV using a
15 w/w% PVP and 3.1 w/w% LAP solution in
1:1 (v:v) DMF:EtOH solvent system. The maximum
flow rate, thus the production rate was determined
to be F = 0.9 ml/h. SEM images of the produced
fiber mats can be seen in Figure 1. The abovemen-
tioned results indicate the need of fine-tuning the
electrospinning conditions, both process and poly-
meric solution related, in order to produce LAP-
loaded PVP nanofibers with maximized LAP content.
The resulting LAP-loaded PVP nanofibers were ran-
domly oriented, smooth-surfaced, and bead-free with
an average fiber diameter of 462±160 nm. As the his-
togram in the inset of Figure 1b shows, the individual
fiber diameters range from ~135 to ~1300 nm; how-
ever, most of the fibers are in the ~400 nm range.
3.2. DSC results
Figure 2 shows the thermograms of the neat poly-
mer, PVP, the active pharmaceutical ingredient,
LAP-DT, and the prepared LAP-loaded PVP nano -
fibers, respectively. The thermogram of PVP shows
a broad endothermic peak between 50 to 125°C, most
probably due to the dehydration of the polymeric
material. The broad endotherm peak did not appear
on the second heating cycle of the heat-cool-heat
DSC cycle. The Tg of amorphous PVP was measured
to be 178.6 °C, which shows good agreement with
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Figure 1. SEM images of LAP-loaded PVP nanofiber mats at a) 500× magnification and at b) 10000× magnification with
the fiber diameter histogram overlayed with the normal distribution from 15 w/w% PVP and 3.1 w/w% LAP so-
lution in 1:1 DMF:EtOH at F = 0.9 ml/h, D = 10 cm and V = 13.5 kV.
the literature [39]. The thermogram of LAP-DT
shows three endotherm peaks with onsets at approx-
imately 125, 166, and 251°C and the related peak
maximums at approximately 133, 175, and 255 °C,
respectively. Peaks at 125 and at 166°C are present
on the thermogram due to the polymorphic structure
of LAP, representing most probably Form II and
Form I crystalline structure of LAP, respectively [40,
41]. The large and narrow endothermic peak at
255 °C indicates the crystal melting and hence the
crystalline nature of LAP-DT. The LAP-loaded PVP
nanofiber thermogram shows a broad peak below
100 °C, most probably a dehydration peak, and a
glass transition region, at Tg = ~167°C. The lack of
any endothermic peak at 255°C can be an indicator
that the LAP-DT is in the amorphous state within the
PVP nanofibers. The decrease in Tg of PVP is due to
the mixing of the two amorphous materials as de-
scribed in the literature [20].
3.3. Raman spectroscopy results
Raman spectroscopy was used to investigate the dis-
tribution of the API in the LAP-loaded PVP nano -
fibers. In order to determine the presence of LAP in
the nanofibers, the Raman spectra of PVP, LAP, and
LAP-loaded PVP nanofibers were collected and pre-
sented in Figure 3. The Raman spectra of LAP show
six distinct peaks/ peak groups, and based on the lit-
erature, these could be assigned for the following
functional groups: at approximately 800 (C–Cl), 1210
(C–O–C), 1300 (O=S=O), 1550, and at 1609 cm–1
[42]. These significant peaks/ peak groups are marked
with an asterisk “*” on the spectra. PVP also shows
peaks at characteristic wavenumbers: 754 (C–C
ring), 851 (C–C), 933 (C–C ring breathing), 1023
(C–C backbone), 1344 and 1370 (C–H deformation),
1425–1456–1494 cm–1 (CH2 scissor) [43]. These
peaks were marked with “◊” in Figure 3. One can
observe that the Raman spectra of LAP-loaded PVP
nanofiber contain both sets of peaks, those that cor-
respond to the PVP structure (marked with “◊”) and
those corresponding to the LAP structure (marked
with “*”). It could also be observed that the peaks
corresponding to LAP in the LAP-loaded PVP nano -
fiber spectra are a bit broader than in the neat drug.
The peak broadening could be attributed to the amor-
phous state of the LAP in the PVP nanofiber [44, 45].
These findings are in good agreement with the DSC
results. Measurements were performed on three dif-
ferent parts of the nanofiber sample, which showed
the same Raman spectra, indicating the homoge-
neous distribution of LAP in the produced solid dis-
persion. Based on these results, we can conclude that
we successfully made an amorphous solid dispersion
of LAP in the PVP nanofiber matrix.
3.4. GC results
As the prepared nanofibrous mats were electrospun
from organic solvents, it is essential to determine the
residual solvent content of the obtained product.
EtOH is a Class 3 solvent with low toxic potential,
as described in ICH Guideline Q3C. These solvents
are less toxic and present a lower risk to human
health. Usually, a limit of 5000 ppm is acceptable for
Class 3 solvents in pharmaceutical products without
justification. DMF, the solvent necessary for dissolv-
ing LAP, is classified as a Class 2 solvent, considered
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Figure 2. DSC thermograms of LAP-DT (blue), PVP (green)
and LAP-loaded PVP nanofibers (black).
Figure 3. Raman spectra of PVP (green), LAP-loaded PVP
nanofibers (black), and LAP (blue) over the wave -
number interval of 1650–430 cm–1.
to be a solvent to be limited because of its inherent
toxicity. The concentration limit for DMF is limited
at 880 ppm.
The determined values of 10.9±2.3 ppm for EtOH
and 780±56 ppm for DMF by GC are below the
abovementioned limits, which means that most of
these solvents evaporate properly during the electro-
spinning process. The presence of lower levels of
EtOH in the fibers is most probably due to the lower
boiling point (78 °C) of the solvent resulting in a
higher evaporation rate during the electrospinning
process, whereas the relatively high amount of DMF
is most probably due to the high boiling point
(153°C) of the solvent, thus the lower evaporation
rate during the electrospinning process. The solvent
levels in the LAP-loaded PVP fibers could be further
lowered using vacuum drying.
3.5. Drug content of the prepared nanofibers
In order to confirm the presence of LAP in the PVP
nanofibers and to determine the drug loading of the
prepared products, HPLC was used. Based on the
HPLC results, the nanofibrous webs contain
16.76±0.11 w/w% LAP (n = 3), which corresponds
to 97.19±0.64% of the theoretical LAP content
(17.24 w/w%). This finding, together with the DSC
and Raman results, indicates that all of the used LAP
to prepare the polymeric solution are present in the
LAP-loaded PVP nanofibers.
3.6. Solubility and in vitro dissolution studies
Solubility of LAP-DT was determined in various
media at 20±2 °C. The results indicate that LAP is
slightly soluble in HCl 0.1 N (297.1±28.4 µg/ml);
however, its solubility rapidly decreases in water
(3.1±0.1 µg/ml), and it is practically insoluble in
0.2 M phosphate buffer pH 6.8 (<0.05 µg/ml).
Figure 4 depicts the comparative dissolution curves
for the LAP-loaded PVP nanofibers and the LAP in
0.1 N HCl (Figure 4a) and 0.2 M phosphate buffer
pH 6.8 (Figure 4b) as dissolution media.
Neat LAP dissolved at low pH (approx. 80%, after
30 min) shown in Figure 4a that correlates well with
the literature [21], due to the presence of the dica-
tionic form. At pH 6.8, where the monocationic and
neutral forms predominate, the dissolved concentra-
tions were lower than the LOQ of the employed chro-
matographic method, Figure 4b. This result corre-
lates well with literature [20] data showing only ~5%
LAP dissolved in 0.2% (w/v) SDS in water dissolu-
tion media where SDS was used to enhance the dis-
solution of LAP. In contrast, the disintegration of the
prepared nanofibrous material was instantaneous,
most probably due to the increased surface area when
it comes in contact with the dissolution media. As it
can be observed from the obtained data, the prepared
LAP-loaded PVP nanofibrous mat solid dispersion
presents ~100% LAP dissolution in the 0.1 N HCl
whereas an over ~60% dissolution even at pH 6.8.
This could most likely be explained by the crys-
talline to amorphous transition of the API by the
electrospinning process. The LAP dissolution results
from the LAP-loaded PVP nanofiber mats correlate
well with the literature [20, 21], thus indicating that
electrospinning is a viable process to prepare LAP-
loaded solid dispersions.
4. Conclusions
In conclusion, solid dispersion of LAP and PVP
were prepared by electrospinning for the first time.
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Figure 4. Dissolution curves of LAP-loaded PVP nanofiber and neat LAP in a) 0.1 N HCl dissolution media and b) 0.2 M
and 0.2 M phosphate buffer pH 6.8.
Using DMSO or DMF alone as solvent did not result
in fiber formation; however, the use of 1:1 ratio of
DMF:EtOH solvent system resulted in a stable elec-
trospinning process. The produced fibers were smooth
surfaced, bead-free, and planarly randomly oriented
with an average fiber diameter of 462±160 nm. DSC
results suggest that LAP is in the amorphous state
within the PVP fiber, whereas Raman spectroscopy
confirms this and indicates a homogeneous distribu-
tion of the cancer drug in the nanofiber mat solid dis-
persion. The dissolution studies further underline
these findings, presenting an increase in solubility
and dissolution of the active ingredient, especially
in pH 6.8, where over 60% is dissolved from the
nanofibrous samples, compared to approximately
0.1% from the neat active ingredient. It was con-
firmed by the GC results that the residual solvent in
the LAP-loaded PVP fibers was below the recom-
mended levels. The obtained results could be a new
starting point for the development of novel LAP for-
mulations with increased solubility and bioavailabil-
ity for breast cancer treatment.
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